Teva is rumored to be close to naming a new CEO, after a tumultuous few months that included the October announcement it was firing 10% of its staff, followed just weeks later with the public departure of then-CEO Jeremy Levin. Whether Levin was pushed or left on his own accord depends on the interviewee, but Eyal Deshesh has filled the role for the last several months.
Bloomberg reported Monday that board member Erez Vigodman is favored for the title, while BioCentury said Friday that Teva would not comment on whether the CEO of agrochemical firm Makhtshim Agan was in line for the job.
